Polymyositis

2
Pipeline Programs
1
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
2
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

KL
Kezar Life SciencesCA - South SF
2 programs
2
KZR-616Phase 21 trial
KZR-616Phase 21 trial
Active Trials
NCT04628936CompletedEst. Jun 2023
NCT04033926CompletedEst. Apr 2022

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Kezar Life SciencesKZR-616
Kezar Life SciencesKZR-616

Clinical Trials (2)

Open-label Extension to the Phase 2 Crossover Study (PRESIDIO) Evaluating KZR-616 in Patients With PM and DM.

Start: Nov 2020Est. completion: Jun 2023
Phase 2Completed

A Phase 2 Study of KZR-616 to Evaluate Safety and Efficacy in Patients With Active Polymyositis or Dermatomyositis

Start: Jan 2020Est. completion: Apr 2022
Phase 2Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 companies competing in this space